false
Catalog
2023 World Conference on Lung Cancer (Posters)
EP11.01. A Multicenter Study of the Association be ...
EP11.01. A Multicenter Study of the Association between TTF-1 and Immunochemotherapy in Lung Adenocarcinoma - PDF(Abstract)
Back to course
Pdf Summary
This abstract highlights the findings of a multicenter study on the association between thyroid transcription factor-1 (TTF-1) and the outcome of immunochemotherapy in lung adenocarcinoma. TTF-1 is known as a good prognostic factor for non-small-cell lung carcinoma, but its role in immunochemotherapy outcomes is not well understood. <br /><br />The study included 95 patients with lung adenocarcinoma who were treated with immunochemotherapy. Tumor samples were re-diagnosed and TTF-1 expression was assessed using immunohistochemical staining. TTF-1 scoring was based on staining intensity and the percentage of positive cells.<br /><br />The results showed that the positivity rate of TTF-1 was 61.1%. Patients with TTF-1 negative had a significantly higher ratio of programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) 1%. The median progression-free survival (PFS) was significantly longer in patients with TTF-1 positive compared to negative. Specifically, patients treated with pemetrexed and TTF-1 positive had a significantly longer PFS than those with TTF-1 negative. On the other hand, the PFS for patients treated with taxane and TTF-1 negative was not inferior to those with TTF-1 positive. Patients with PD-L1 TPS 1% and TTF-1 scoring of 0 had a significantly worse PFS.<br /><br />The authors conclude that TTF-1 may be a good prognostic factor for pemetrexed-based immunochemotherapy in lung adenocarcinoma. They suggest that TTF-1 staining could be used to develop more optimal treatments for this type of cancer.
Asset Subtitle
Nanami Yamasaki
Meta Tag
Speaker
Nanami Yamasaki
Topic
Metastatic NSCLC: Immunotherapy - Biomarker
Keywords
Thyroid transcription factor-1
TTF-1
lung adenocarcinoma
immunochemotherapy
prognostic factor
immunohistochemical staining
PD-L1
tumor proportion score
progression-free survival
pemetrexed-based immunochemotherapy
×
Please select your language
1
English